A history of traumatic brain injury (TBI) significantly reduces the diagnostic accuracy of Alzheimer disease blood biomarkers, according to a cross-sectional study published in JAMA Neurology in 2026. Researchers found that while plasma p-tau217/Aβ42 ratios are highly accurate in individuals without TBI, the test’s sensitivity drops sharply as the severity of a prior head injury increases.
How does TBI history affect Alzheimer blood test accuracy?
The accuracy of the plasma p-tau217/Aβ42 ratio—a biomarker used to detect brain amyloid—is closely tied to an individual’s history of brain trauma. According to the study led by Y. Rosen-Lang and colleagues, the test reached 90% accuracy in veterans with no prior TBI. However, that figure fell to 78% in veterans who experienced a TBI with a loss of consciousness lasting up to five minutes. For those who lost consciousness for more than five minutes, diagnostic accuracy dropped to 63%.
Did you know? Researchers analyzed data from 272 Vietnam War veterans between 2024 and 2025 to determine how neurological history influences the performance of modern blood-based diagnostic tools for Alzheimer disease.
Why do blood biomarkers miss amyloid cases in TBI patients?
The reduced diagnostic performance is primarily driven by lower sensitivity, meaning the test is more likely to yield false negatives in patients with a history of TBI. Even when researchers accounted for variables like TBI occurring within the previous 10 years, the patterns of decreased accuracy remained consistent. According to the study, similar performance declines were observed when testing plasma p-tau217 alone and the plasma Aβ42/40 ratio, suggesting that the physiological impact of TBI may alter the presence or detection of these specific proteins in the blood.
Comparison of Diagnostic Accuracy by TBI Severity
| TBI History | Test Accuracy |
|---|---|
| No TBI | 90% |
| TBI (LOC 0–5 minutes) | 78% |
| TBI (LOC >5 minutes) | 63% |
What are the clinical implications for future diagnostics?
As blood-based testing becomes a more common component of diagnostic pathways for neurodegenerative conditions, clinicians must exercise caution. The authors of the JAMA Neurology study warn that relying solely on the p-tau217/Aβ42 ratio could cause providers to miss more than half of amyloid-positive cases in patients with a history of TBI. This is particularly concerning for individuals who are either cognitively unimpaired or showing only mild cognitive impairment.
Pro Tip: When evaluating patients for Alzheimer disease, medical professionals should consider a patient’s full neurological history—including past traumatic brain injuries—to better interpret the reliability of blood biomarker results.
Frequently Asked Questions
Are blood tests for Alzheimer’s reliable for everyone?
Not necessarily. Recent data indicates that a history of TBI can lower the accuracy of these tests, making them less reliable for veterans or others with significant head injury history.
Does TBI cause Alzheimer disease?
The study focuses on how TBI history modifies the *accuracy* of diagnostic blood tests, rather than establishing a direct causal link to the development of Alzheimer disease itself.
Should I be worried if I have a history of TBI?
If you have concerns about cognitive health, consult a neurologist. The study suggests that physicians should interpret blood biomarker results with caution if a patient has a documented history of TBI.
Have questions about how new diagnostic technologies are changing the way we understand brain health? Subscribe to our newsletter for the latest medical research updates, or leave a comment below to share your perspective.
Worth a look
